Company / SG&A Expense
InMed Pharmaceuticals Inc. SG&A Expense History
FY2022-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$5.8M
FY2025
5-year range
$4.5M / $6.9M
FY2022-FY2025
Trend
-0.8%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $7M to $6M over the past 2 years.
Based on SEC 10-K filings.
$6M in FY2025 with a 3-year CAGR of +9.0%.
Improved from $7M to $6M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- +9.0%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of +9.0%, indicating consistent growth.
- In FY2025, sg&a expense decreased 0.8% year-over-year.
Company context
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $5.8M | -0.8% |
| FY2024 | $5.8M | -14.8% |
| FY2023 | $6.9M | +53.3% |
| FY2022 | $4.5M | - |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026